The International Core is designed specifically to support the international research base of UNC, FHl, and RTI, including collaborating in-country investigators, foster synergy across the Cores and CFARs, and enhance HIV/AIDS research collaborations in key countries: Malawi, South Africa, the Democratic Republic of Congo (DRC), China, Russia, and in Central America, Nicaragua and Guatemala. The sheer volume and density of HIV in our collaborating sites allows research questions to be addressed with speed and efficiency impossible in places with lower HIV prevalence. A substantial part ofthe UNC CFAR's NIH support for HIV research comes for work undertaken outside the United States. This has involved leadership roles in the nternational NIH networks, including HPTN, the International ACTG, the CHAVI (Center for HIV Vaccine Immunology), Microbicide Trials Network and IMPAACT. UNC's global AIDS programs have led to the formation of an NIH HIV Clinical Trials Unit (CTU) in Lilongwe, Malawi, widely viewed as one ofthe best and most productive in the NIH Networks. Investigator-initiated research on HIV clinical care and biological and social factors related to HIV transmission and prevention of transmission is ongoing in Malawi, South Africa, China, the DRC, and Russia;research devoted to STD and HIV overlap has been a focus in China. UNC investigators have participated in virtually all Fogarty research Training Programs including AITRP, the Fogarty Center for Bioethics in Francophone Africa, the ICORTA-TB/AIDS, and the Fogarty Ellison pre- and post-doctoral programs. The Core provides: support for basic, clinical, and behavioral/social science infrastructure and capacity building;training in-country and at UNC in protocol development, IRB, and regulatory;and consideration of a range of ethical challenges raised by international research collaborations. The Core has provided leadership in facilitating cross-Core collaborations, mentoring junior investigators, manuscript and grant preparation for international collaborators, and communicating results from international research.

Public Health Relevance

The International Core will impact public health in several ways. By investing in laboratory infrastructure, clinical and social/behavioral research capacity, development of clinical databases and specimen repositories, and mentored training needed to sustain these investments, the Core has facilitated important scientific and clinical discoveries that have been translated into improved medical treatment for people most affected by the HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050410-15
Application #
8379681
Study Section
Special Emphasis Panel (ZAI1-ELB-A)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
15
Fiscal Year
2012
Total Cost
$139,534
Indirect Cost
$42,192
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Buchanan, Ashley L; Hudgens, Michael G; Cole, Stephen R et al. (2018) Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights. J R Stat Soc Ser A Stat Soc 181:1193-1209
Muessig, Kathryn E; Knudtson, Kelly A; Soni, Karina et al. (2018) ""I DIDN'T TELL YOU SOONER BECAUSE I DIDN'T KNOW HOW TO HANDLE IT MYSELF."" DEVELOPING A VIRTUAL REALITY PROGRAM TO SUPPORT HIV-STATUS DISCLOSURE DECISIONS. Digit Cult Educ 10:22-48
Bradley, Todd; Ferrari, Guido; Haynes, Barton F et al. (2018) Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. Cell Rep 25:107-117.e3
Adimora, Adaora A; Ramirez, Catalina; Benning, Lorie et al. (2018) Cohort Profile: The Women's Interagency HIV Study (WIHS). Int J Epidemiol 47:393-394i
Garrett, Katy L; Chen, Jingxian; Maas, Brian M et al. (2018) A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. J Pharmacol Exp Ther 367:245-251
Ong, Jason J; Wei, Chongyi; Pan, Stephen et al. (2018) Individuals have the right to avoid sex with partners unwilling to test for HIV but do not have a right to force them to test for HIV. J Acquir Immune Defic Syndr :
Qin, Yilu; Han, Larry; Babbitt, Andrew et al. (2018) Experiences using and organizing HIV self-testing. AIDS 32:371-381
Hightow-Weidman, Lisa B; Muessig, Kathryn; Rosenberg, Eli et al. (2018) University of North Carolina/Emory Center for Innovative Technology (iTech) for Addressing the HIV Epidemic Among Adolescents and Young Adults in the United States: Protocol and Rationale for Center Development. JMIR Res Protoc 7:e10365
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Henderson, Gail E; Peay, Holly L; Kroon, Eugene et al. (2018) Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment. J Med Ethics 44:270-276

Showing the most recent 10 out of 1688 publications